The use of fragment-based drug discovery to develop novel small molecules that modulate the BRCA2-RAD51 interaction for the treatment of cancer

Informazioni relative al progetto

BRCA2-RAD51

ID dell’accordo di sovvenzione: 274569

Progetto chiuso

Data di avvio 1 Marzo 2011

Data di completamento 28 Febbraio 2013

Finanziato da

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Costo totale € 201 049,60

Contributo UE € 201 049,60

Coordinato da

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom